ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.290,08
-0,13%
Dow Jones
39.895,18
0,06%
Euro vs US Dollar
1,08728
0,05%
Bitcoin
66.472,92
1,89%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Halozyme Therapeutics Incorporated (HALO)

  7. Halozyme Therapeutics Incorporated (HALO) News

HALO

Halozyme Therapeutics (HALO)

Halozyme Therapeutics Incorporated
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:HALO
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202414h30PR Newswire (US)Halozyme to Participate in Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202422h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HALOHalozyme Therapeutics Incorporated
07/05/202422h01PR Newswire (US)HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
25/04/202422h45PR Newswire (US)Mahesh Krishnan Elected to Halozyme's Board of DirectorsNASDAQ:HALOHalozyme Therapeutics Incorporated
23/04/202414h30PR Newswire (US)Halozyme to Report First Quarter 2024 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
04/03/202422h13Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:HALOHalozyme Therapeutics Incorporated
29/02/202400h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
28/02/202422h07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/02/202423h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/02/202423h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/02/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/02/202422h08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
27/02/202414h30PR Newswire (US)Halozyme to Participate in Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
21/02/202400h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
21/02/202400h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
21/02/202400h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
21/02/202400h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
20/02/202422h07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HALOHalozyme Therapeutics Incorporated
20/02/202422h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HALOHalozyme Therapeutics Incorporated
20/02/202422h01PR Newswire (US)HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
16/02/202423h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
16/02/202423h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
16/02/202423h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
13/02/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
13/02/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
13/02/202422h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
12/02/202412h19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HALOHalozyme Therapeutics Incorporated
08/02/202422h30PR Newswire (US)Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
29/01/202422h15PR Newswire (US)Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NASDAQ:HALOHalozyme Therapeutics Incorporated
 Showing the most relevant articles for your search:NASDAQ:HALO

Kürzlich von Ihnen besucht

TG
NOV
Novo Nordisk
USOTC
BASFY
BASF (QX)
COIN
SOLUSD
Solana
TG
432
Arbor Metals
TG
BAS
BASF
DBI
MDAX
MDAX
TG
CBK
Commerzbank
AMEX
XLE
Energy Select Sector SPDR
NYSE
XOM
Exxon Mobil
DBI
TDXP
Tec DAX
FX
EURGBP
Euro vs Sterling
DBI
SDXP
SDAX
CCOM
US500
US 500
NASDAQ
AAPL
Apple
DBI
DAX
DAX
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten